WO2026003803 - TIVOZANIB FOR TREATING POSTERIOR SEGMENT EYE DISEASES
National phase entry is expected:
Publication Number
WO/2026/003803
Publication Date
02.01.2026
International Application No.
PCT/IB2025/056566
International Filing Date
27.06.2025
Title **
[English]
TIVOZANIB FOR TREATING POSTERIOR SEGMENT EYE DISEASES
[French]
TIVOZANIB POUR LE TRAITEMENT DE PATHOLOGIES DU SEGMENT POSTÉRIEUR DE L'ŒIL
Applicants **
KYOWA KIRIN CO., LTD.
Inventors
HORITA, Shinya
Priority Data
63/665,784
28.06.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5659 | |
| EPO | Filing, Examination, Granting | 145569 | |
| Japan | Filing, Examination, Granting | 5025 | |
| South Korea | Filing, Examination, Granting | 9925 | |
| USA | Filing, Examination, Granting | 33140 |
Total:
199,318
Contact Us
Abstract[English]
Disclosed are methods of treating a human patient with a posterior segment eye disease, the method comprising topically administering a maintenance effective dose of a tivozanib formulation as a maintenance phase dose or a therapeutically effective dose of a tivozanib formulation 1 to 3 times per day to the eye of the human patient. The method may further comprise an induction phase treatment with an anti-VEGF agent.[French]
L'invention concerne des méthodes de traitement d'un patient humain atteint d'une pathologie du segment postérieur de l'œil, la méthode comprenant l'administration topique d'une dose de maintenance efficace d'une formulation de tivozanib en tant que dose de phase de maintenance ou d'une dose thérapeutiquement efficace d'une formulation de tivozanib 1 à 3 fois par jour dans l'œil du patient humain. Le procédé peut en outre comprendre un traitement en phase d'induction avec un agent anti-VEGF.